Biotech Values

[RockRat]

I agree it seems as though it would be in their interest to say so, but . . . with mEnoxaparin on the market with a good head start, the tEnoxaprin revenue stream, while worth pursuing, isn't going to amount to much relative to Teva's market cap. This stuff was only barely material to them before mEnoxaparin approval, and it is not directly material now. So they may have decided to move on to other things when they do presentations.

In contrast, it was very material to Momenta, so we heard about their inspections pretty promptly. We all know that strategically, Momenta is arguably the biggest threat to Teva, so anything they can say -- or refrain from saying -- to create uncertainty for Momenta . . . they would. I was being a little facetious in saying I was guessing Bill Marth, btw. And I fail to see how this response is stupid. We can just agree to disagree here.

All I am saying is this: my expectation of imminent tEnoxaparin approval is somewhat higher than before. If that expectation turns out to be wrong -- and I dearly hope it does -- than I guess we have another data point for the delcine in Teva's vaunted credibility. This is just the first shot in the campaign, hopefully. Hopefully the question will be asked again, hopefully in public, and hopefully we'll get a better read.

You're welcome.

Regards, RockRat